Clinical trials: open to volunteers, sponsored by M.D. Anderson Cancer Center
Occupational Stress
Evaluating Occupational Stress in Surgeons and Musicians: A Multi-modal Pilot Study Using Wearable EEG, Biomarker Analysis and Validated Questionnaires
To learn about occupational stress among surgeons and musicians by integrating psychological assessments, neurophysiological measures, and biomarkers.
- Trial name
- NCT06875882
- Testing
- Occupational Stress in Surgeons and Musicians
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Spinal Metastasis
A Phase I Study of the NovoTTF-200M and Novo TTF-200A Systems for the Treatment of Refractory Spinal Metastasis
This clinical research study is to learn about the safety of the NovoTTF-200M and Novo TTF-200A Systems, when used either alone or in combination with standard therapy, in patients with tumors that did not respond to treatment.
- Trial name
- NCT06906900
- Testing
- TTF-200M and TTF-200A systems
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Comparative Performance of Molecular Breast Imaging (MBI) to Magnetic Resonance Imaging (MRI) of the Breast in Identifying and Excluding Breast Carcinoma in Women at High Risk for Breast Cancer
To evaluate the diagnostic performance of Tc99m sestamibi (MBI) compared to breast MRI in women who are at high risk for developing breast cancer.
- Trial name
- NCT05042687
- Testing
- Tc99m sestamibi
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- M.D. Anderson Cancer Center
Bladder Cancer
Measuring Surgical Recovery After Radical Cystectomy
The intent of this study is to establish a registry of post-surgical outcomes in patients undergoing radical cystectomy at MD Anderson Cancer Center and the collaborating institutions.
- Trial name
- NCT03193970
- Testing
- Post-Operative Recovery Registry
- Where
- 10 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Adenocarcinoma, Oligometastasis
Chemotherapy With or Without Radiation or Surgery in Treating Participants With Oligometastatic Esophageal or Gastric Cancer
This phase II trial studies how well chemotherapy with or without radiation or surgery works in treating participants with esophageal or gastric cancer that has spread to less than 3 places in the body (oligometastatic).
- Conditions
- Gastric Adenocarcinoma, Oligometastasis, Stage IV Esophageal Adenocarcinoma AJCC v7, Stage IV Esophageal Cancer AJCC v7
- Trial name
- NCT03161522
- Testing
- Capecitabine, Chemotherapy, Conventional Surgery
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Targeted Therapy, IDH1-Mutated Malignancies
Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
To learn about the safety and tolerability of study drug combinations in patients with relapsed/refractory, IDH1-mutated myeloid malignancies with a co-signaling mutation.
- Conditions
- Targeted Therapy, IDH1-Mutated Malignancies, Mutations
- Trial name
- NCT07032727
- Testing
- Olutasidenib, Cladribine (CLAD), Venetoclax
- Where
- 2 sites in United States
- Volunteers
- 68 people
- Sponsor
- M.D. Anderson Cancer Center
Lymphoma
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
To assess the efficacy and safety of mosunetuzumab combined with zanubrutinib in patients with relapsed or refractory MZL.
- Trial name
- NCT06563505
- Testing
- Mosunetuzumab, Zanubrutinib
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Malignancies
A Phase II Open-label Study of Olutasidenib Post-transplant Maintenance Therapy for Patients With IDH1-mutated Myeloid Malignancies
The goal of this clinical research study is to learn about the safety and tolerability of giving olutasidenib to patients with IDH1-mutated myeloid malignancies as maintenance therapy after they receive a stem cell transplant.
- Trial name
- NCT06668584
- Testing
- Olutasidenib
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- M.D. Anderson Cancer Center
Urothelial Carcinoma
Prospective Collection And Molecular Analysis Of Biospecimens And Clinical Data From Patients With Urothelial Carcinoma And Related Malignancies Of The Urinary Tract
To collect, process, store, and study biological samples and related clinical and imaging data from participants with known or suspected urothelial carcinoma or another related malignancy of the urinary tract.
- Trial name
- NCT07789119
- Testing
- biospecimen Collection
- Where
- United States
- Volunteers
- 50,000 people
- Sponsor
- M.D. Anderson Cancer Center
Head and Neck Cancer
A Ph2, Colchicine For Inflammatory Carotid Injury And Disease Evolution After Radiotherapy
The goal of this clinical research study is to find out if low-dose colchicine (an anti-inflammatory drug) lowers the rate of radiation-related side effects to the carotid artery in patients who have completed radiation therapy…
- Trial name
- NCT07856719
- Testing
- Colchicine
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- M.D. Anderson Cancer Center
Phase 2 Study, BMS-986504
A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer
To find out if the combination of BMS-986504 plus neoadjuvant/adjuvant chemotherapy and surgery (Cohort 1) or BMS-986504 plus standard of care chemotherapy (Cohorts 2 and 3) can help to control pancreatic cancer.
- Conditions
- Phase 2 Study, BMS-986504, MTAP-deleted Pancreatic Cancer
- Trial name
- NCT07283705
- Testing
- BMS-986504, Gemcitabine, Nab-paclitaxel
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Cancer
Supporting Families In Coping With Parental Cancer: A Multi-Site Randomized Controlled Trial
The goal of this behavioral research study is to learn about the effect of a parent support intervention on cancer patients' and their family caregivers' mental wellbeing, and family functioning.
- Trial name
- NCT07852858
- Testing
- Parent Support Intervention
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
AML
Phase1b/2 Trial Of AZA + APG1252 In Patients With High-Risk AML
This is a phase Ib/II study that aims to investigate the safety, tolerability and explore the efficacy of BCL- XL inhibition in participants with high-risk AML.
- Trial name
- NCT07508982
- Testing
- Azacitidine, APG1252
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- M.D. Anderson Cancer Center
Phase 1, Recurrent Melanoma
Phase 1 Dose Escalation and Expansion Study of PRAME T Cell Receptor (TCR) Engineered NK Cells in Participants With Recurrent and/or Refractory Melanoma (PRAMETIME-Mel)
To find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
- Conditions
- Phase 1, Recurrent Melanoma, Refractory Melanoma
- Trial name
- NCT06660420
- Testing
- Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- M.D. Anderson Cancer Center
Mutant IDH1 Inhibitor Olutasidenib
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
- Trial name
- NCT06445959
- Testing
- Olutasidenib, Venetoclax, Decitabine
- Where
- 5 sites in United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Relapsed/Refractory Myeloma
Ph I/II Trial of Cord Blood-derived NK Cells With NY-ESO-1 TCR/IL-15 for R/R Myeloma
To find the recommended dose of NY-ESO-1 TCR/IL-15 NK cells that can be given to patients with relapsed or refractory MM. To learn if the dose of NY-ESO-1 TCR/IL-15 NK cells found in Part A can help to control the disease.
- Trial name
- NCT06066359
- Testing
- Fludarabine phosphate, Cyclophosphamide, Allogeneic Anti-NY-ESO-1-TCR-IL-15-transduced Cord Blood-derived Natural Killer Cells
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- M.D. Anderson Cancer Center
Prospective Study , Questionaires, Outcomes
Prospective Study To Assess The Outcomes Of Nitrous Oxide Cryoablation For Treatment Of Duodenal Adenomas In Patients With Hereditary Conditions Such As FAP, HNPCC
To learn how well nitrous oxide cryoballoon ablation, a procedure that uses extreme cold to destroy abnormal tissue, works in treating flat duodenal adenomas (abnormal growths in the small intestine) in people with FAP or Lynch…
- Conditions
- Prospective Study , Questionaires, Outcomes, Nitrous Oxide, Cryoablation
- Trial name
- NCT07859514
- Testing
- Esophagogastroduodenoscopy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia
This phase II trial studies how well venetoclax, cladribine, low dose cytarabine, and azacitidine work in treating patients with acute myeloid leukemia that has previously not been treated.
- Trial name
- NCT03586609
- Testing
- Azacitidine, Cladribine, Cytarabine
- Where
- United States
- Volunteers
- 145 people
- Sponsor
- M.D. Anderson Cancer Center
Psilocybin, Neuropathy
NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy
To learn if psilocybin can help to prevent or decrease the severity of chemotherapy-induced peripheral neuropathy (CIPN) in patients who are receiving chemotherapy for the treatment of breast, colorectal, and In this study…
- Trial name
- NCT07227909
- Testing
- Psilocybin (drug), Standard of Care (SOC)
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Colorectal Cancer, Peritoneal Metastases
Dual Administration Of Intraperitoneal And Intravenous TROP2-Directed CAR-NK With TGF-Beta Receptor 2 (TGFBR2) Knock Out (KO) Therapy For Colorectal Cancer-Related Peritoneal Carcinomatosis: A Phase 1/2 Trial ("Chip-CRC Trial")
To find the highest dose of NK cells that can be given by vein and intraperitoneally (given directly into the abdominal cavity) in combination with cetuximab to patients with colorectal cancer that has spread to the peritoneum.
- Conditions
- Colorectal Cancer, Peritoneal Metastases, Carcinomatosis
- Trial name
- NCT07411599
- Testing
- Cyclophosphamide, Fludarabine, Cetuximab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center